HeartWare International Inc

HeartWare International — Technical Presentation (April 2011)

19 slides from HeartWare International's technical presentation, Apr 18, 2011

  1. Slide 1: Evaluation of the HeartWare HVAD LVAS: ADVANCE BTT Trial Results and Continued Access Update

    Evaluation of the HeartWare HVAD Left Ventricular Assist System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial and Update with Continued Access Patients M Slaughter, K Aaronson, S Boyce, LW Miller, EC McGee, WG Cotts, M Acker, ML Jessup, ID Gregoric, P

  2. Slide 2: HeartWare Ventricular Assist System

    HeartWare Ventricular Assist System HVAD miniaturized implantable blood pump Pericardial placement - no pump pocketProvides up to 10 L/min of flowCentrifugal design, continuous flowHybrid magnetic / hydrodynamic impeller suspensionOptimizes flow, pump surface washing, and hemocompatibilityThin (4.2

  3. Slide 3: ADVANCE Trial Design

    Multi-site (30), prospective trial to evaluate the HeartWare HVAD as a bridge-to-transplant in the USEnrollment period was August 2008 to February 2010 All patients were followed for ^ 180 days following implant or until cardiac transplantation, device explant for recovery or deathTreatment group wa

  4. Slide 4: Recap of Results of the ADVANCE Trial

    "Success" was 92% - survival to 180 days on original device or transplantSurvival at 180 days was 94% Non-inferiority to INTERMACS control was established (p < 0.0001) Recap of Results of the ADVANCE Trial

  5. Slide 5: Continued Access Protocol for ADVANCE Trial

    Continued Access Protocol for ADVANCE Trial Continued access for the bridge-to-transplant indication was approved for the 30 sites that enrolled at least 1 patient in ADVANCEThe same enrollment protocol is in effect for CAP 3 allotments of additional patients (54, 54 and 94) have been granted by the

  6. Slide 6: CAP Enrollment

    CAP Enrollment Actual CAP Enrollment to March 2011 3 2 g s 5 E 5 é © 9 a9 a9 a9 as aos asi aos ass as 99 PP 9 209 19 2 2M 29 a a9 a SPA eB se Gee OSH goth ge woh ceo™ ot

  7. Slide 7: Baseline Characteristics

    Baseline Characteristics ADVANCE (N = 140) CAP (N =110) Age (years) 53. 3 + 10.3 52 + 13.4 Male sex (%) 101 (72) 76 (66) Race [number (%)] White 102 (73) 76 (66) Black/African American 32 (23) 31 (27) Hispanic/Other 6 (3.3) 8 (7) Body-mass index (kg/m2) 28.6 + 6.1 28.8 + 6.2 Body surface area (m2) 2

  8. Slide 8: Baseline Characteristics

    Baseline Characteristics ADVANCE (N = 140) CAP (N = 110) Left ventricular ejection fraction (%) 17.8 + 7.1 17.5 + 7.4 Arterial blood pressure (mm Hg) Systolic 104 + 16 103 + 16 Diastolic 64 + 11 68 + 13 Mean 77 + 13 81 + 12 Pulmonary capillary wedge pressure (mm Hg) 23 + 9 23 + 8 Cardiac index (lite

  9. Slide 9: INTERMACS Classification

    INTERMACS Classification ADVANCEPatients (%) CAPPatients (%) INTERMACS 1 7 (5.0) 4 (4.0) INTERMACS 2 39 (27.9) 35 (34.7) INTERMACS 3 62 (44.3) 48 (47.5) INTERMACS 4-7 32 (22.3) 14 (12.7) CAP patients appear to have more advanced disease by INTERMACS criteria. 250 patients; 174 patient-years

  10. Slide 10: Adverse Events

    Adverse Events Events0-30 Days Events> 30 Days Event Rate* Event Rate* AHA† Bleeding requiring re-op 23 0 0.13 0.20 GI bleeding (22 patients; 8.8%) 11 28 0.22 0.23 Neurological events Ischemic CVA 12 6 0.10 0.10 Hemorrhagic CVA 3 5 0.05 0.06 TIA 2 7 0.05 0.09 Venous thrombosis 8 4 0.07 0.09 Arterial

  11. Slide 11: Adverse Events

    Adverse Events 250 patients; 174 patient-years Events0-30 Days Events> 30 Days Event Rate* Event Rate* AHA Infections Driveline exit 4 25 0.17 0.22 Sepsis 11 20 0.18 0.16 Respiratory dysfunction 38 19 0.33 0.45 Arrhythmia Ventricular 33 29 0.36 0.29† Supraventricular 42 4 0.26 - Right heart failure

  12. Slide 12: Device Exchange

    Device Exchange Reasons for ExchangeGraft Infection (1) BiVAD (1) Tissue in Connector (1) Iatrogenic (3) Thrombus (11) * 5 patients treated with LV tPA - not exchanged

  13. Slide 13: Aspirin Showed Benefit Without Increased GI Bleeding or Hemorrhagic Stroke

    325 mg Aspirin Showed Benefit Without Increased GI Bleeding or Hemorrhagic Stroke GI Bleeding or Hemorrhagic Stroke GI Bleeding or Hemorrhagic Stroke Mean INR 2.1

  14. Slide 14: Strokes

    Strokes Total Disabling† Rate (events PPY§) Hemorrhagic Strokes 8 6 (75%) 0.03 Ischemic Strokes 18 6 (33%) 0.03 † Defined as a Modified Rankin Score of > 4§ Disabling strokes, events/patient-year

  15. Slide 15: Freedom from Major Infections

    Freedom from Major Infections DrivelineSepsis 91% 89% 85% 90% 85% 81%

  16. Slide 16: Survival for ADVANCE and CAP

    Survival for ADVANCE and CAP CAPADVANCE (BTT) 98% 95% 92% 97% 94% 86% 98% 96%

  17. Slide 17: Causes of Death for ADVANCE and CAP

    Causes of Death for ADVANCE and CAP Causes Number of Patients Multisystem Organ Failure 10 Intracerebral Bleeding 4 Right Heart Failure 4 Undetermined 2 Respiratory Failure 1 Sepsis 1 Bone Marrow Suppression 1 Controller failure 1 TOTAL 24 N = 250 patients

  18. Slide 18: Survival Post-Transplant

    Survival Post-Transplant 95% 93% 93% N = 78 patients

  19. Slide 19: Summary

    Summary 250 patients have been enrolled in ADVANCE and CAP for 174 patient-years of support.Survival remains high in CAP, confirming ADVANCE results.Sepsis and driveline infections were notably infrequent. Full dose aspirin (325 mg) was associated with low risk of pump thrombus without increased ris

HeartWare International — Technical Presentation (April 2011) on 6ix